- Home
- BRNS vs BLRX Comparison
BRNS vs BLRX Comparison
Compare BRNS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- BLRX
- Stock Information
- Founded
- BRNS 2016
- BLRX 2003
- Country
- BRNS United Kingdom
- BLRX Israel
- Employees
- BRNS N/A
- BLRX N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- BLRX Health Care
- Exchange
- BRNS Nasdaq
- BLRX Nasdaq
- Market Cap
- BRNS 52.0M
- BLRX 54.1M
- IPO Year
- BRNS 2021
- BLRX 2011
- Fundamental
- Price
- BRNS $1.19
- BLRX $0.46
- Analyst Decision
- BRNS Strong Buy
- BLRX Strong Buy
- Analyst Count
- BRNS 2
- BLRX 2
- Target Price
- BRNS $4.00
- BLRX $11.50
- AVG Volume (30 Days)
- BRNS 39.3K
- BLRX 308.2K
- Earning Date
- BRNS 11-07-2024
- BLRX 11-18-2024
- Dividend Yield
- BRNS N/A
- BLRX N/A
- EPS Growth
- BRNS N/A
- BLRX N/A
- EPS
- BRNS N/A
- BLRX N/A
- Revenue
- BRNS N/A
- BLRX $17,048,000.00
- Revenue This Year
- BRNS $27.18
- BLRX N/A
- Revenue Next Year
- BRNS N/A
- BLRX N/A
- P/E Ratio
- BRNS N/A
- BLRX N/A
- Revenue Growth
- BRNS N/A
- BLRX N/A
- 52 Week Low
- BRNS $1.11
- BLRX $0.43
- 52 Week High
- BRNS $5.10
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- BRNS 42.84
- BLRX 26.70
- Support Level
- BRNS $1.15
- BLRX $0.43
- Resistance Level
- BRNS $1.35
- BLRX $0.56
- Average True Range (ATR)
- BRNS 0.07
- BLRX 0.05
- MACD
- BRNS 0.01
- BLRX -0.01
- Stochastic Oscillator
- BRNS 20.00
- BLRX 12.42
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.